Megan Majocha, PhD

Présence dans les classements

Les meilleurs jours où les posts de ce compte sont entrés dans le top quotidien de Debya.

Ce compte n’est encore apparu dans aucun classement quotidien.

Posts aimés récemment

J’aime publics du réseau Bluesky.

• Susan G. Komen@susangkomen.bsky.social30/05/2026 23:33

  Phase 3 KEYNOTE-522 final results 👀💥 Javier Cortes, MD, PhD presents data from the trial evaluating pembrolizumab + chemo before surgery, followed by adjuvant pembrolizumab vs placebo. #ASCO26 @ascocancer.bsky.social

  Voir le post
• Susan G. Komen@susangkomen.bsky.social30/05/2026 20:29

  Can some people safely avoid chemo in higher-risk early breast cancer? 🤔 OPTIMA phase 3 tests a genomic-guided strategy vs standard of care in HR+/HER2- #breastcancer. Robert Stein, PhD presents first results at #ASCO26 @ascocancer.bsky.social

  Voir le post
• Susan G. Komen@susangkomen.bsky.social30/05/2026 20:29

  New biomarker insights from NATALEE trial presented by Stephen Chia, MD 📊 Baseline gene expression shows prognostic & predictive impact in HR+/HER2- early #breastcancer treated with adjuvant ribociclib + aromatase inhibitor #ASCO26 @ascocancer.bsky.social

  Voir le post
• Susan G. Komen@susangkomen.bsky.social30/05/2026 20:29

  Recurrence remains a challenge in HR+/HER2- early #breastcancer. Phase 3 lidERA trial previously showed improvement with giredestrant (oral SERD) vs standard hormone therapy 📈 Peter Schmid, MD, PhD presents results by menopausal status at #ASCO26 @ascocancer.bsky.social

  Voir le post
• Susan G. Komen@susangkomen.bsky.social12/12/2025 15:43

  🚀 At #SABCS25, Ben Park, MD, PhD showed how cell signals go "off the rails" in breast cancer and how his groundbreaking work with cfDNA is changing care by helping earlier detection, better treatment tracking, and spotting metastasis sooner. @sabcs.bsky.social

  Voir le post

Connectez-vous pour en voir plus

Comptes bloqués

Sur Bluesky, les blocages sont publics.

Ce compte ne bloque personne.